07:52 AM EDT, 08/28/2026 (MT Newswires) -- Drugmaker Eli Lilly (LLY.SW, LLY.F) said Friday the US Food and Drug Administration approved Mounjaro, a dual GIP and GLP-1 hormone receptor agonist, to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for cardiovascular events. The approval expands Mounjaro's use beyond improving blood-sugar levels, for which it is already approved in adults and children 10 years of age and older with type 2 diabetes. The new indication covers reducing the risk of cardiovascular death, nonfatal heart attack, and nonfatal stroke.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.